Physician profile
Amanda Kovacs
NPI 1588199806
$4,302.09
in general payments reported to CMS, 2019-2025
24 companies · $644 in 2025
The $644 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $401 · 2021: $688 · 2022: $426 · 2023: $615 · 2024: $850 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,108.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $498.86 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $494.52 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $405.33 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $340.59 | 2022-2025 | Clareon, Precision7, Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $332.71 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $297.51 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $267.46 | 2024-2025 | Acuvue |
| Abbvie INC. | $260.25 | 2022-2024 | |
| Aerie Pharmaceuticals, INC. | $236.06 | 2019-2021 | |
| Rxsight INC | $220.75 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Horizon Therapeutics Plc | $168.15 | 2022-2023 | Tepezza |
| Amgen INC. | $164.26 | 2024-2025 | Tepezza |
| Shire North American Group INC | $137.76 | 2019 | |
| Thea Pharma INC. | $94.53 | 2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $88.89 | 2022-2023 | Tyrvaya |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $54.90 | 2019-2022 | |
| Dompe US, INC. | $52.91 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $40.10 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $35.36 | 2024 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $30.30 | 2020-2021 | |
| Harrow Eye, LLC | $24.79 | 2024 | Vevye |
| Quidel Corporation | $23.22 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $17.57 | 2020 | |
| Omeros Corporation | $15.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Kovacs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.